tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Fulcrum Therapeutics announces $150M offering of common stock
PremiumThe FlyFulcrum Therapeutics announces $150M offering of common stock
12d ago
Fulcrum Therapeutics price target raised to $25 from $20 at Stifel
Premium
The Fly
Fulcrum Therapeutics price target raised to $25 from $20 at Stifel
13d ago
Fulcrum Therapeutics price target raised to $24 from $15 at Cantor Fitzgerald
Premium
The Fly
Fulcrum Therapeutics price target raised to $24 from $15 at Cantor Fitzgerald
13d ago
Fulcrum announces results from 20 mg dose cohort of Phase 1b PIONEER trial
PremiumThe FlyFulcrum announces results from 20 mg dose cohort of Phase 1b PIONEER trial
13d ago
Fulcrum Therapeutics initiated with a Buy at Truist
Premium
The Fly
Fulcrum Therapeutics initiated with a Buy at Truist
27d ago
Buy Rating for Fulcrum Therapeutics Driven by Promising PIONEER Study Results and Market Potential of Pociredir
Premium
Ratings
Buy Rating for Fulcrum Therapeutics Driven by Promising PIONEER Study Results and Market Potential of Pociredir
27d ago
Fulcrum Therapeutics resumed with a Buy at Stifel
PremiumThe FlyFulcrum Therapeutics resumed with a Buy at Stifel
1M ago
Fulcrum Therapeutics’ Earnings Call Highlights Progress and Potential
Premium
Company Announcements
Fulcrum Therapeutics’ Earnings Call Highlights Progress and Potential
2M ago
Fulcrum Therapeutics price target raised to $16 from $12.50 at Piper Sandler
Premium
The Fly
Fulcrum Therapeutics price target raised to $16 from $12.50 at Piper Sandler
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100